Updates are available Correction dated 2022-12-26
Click to view Correction: https://doi.org/10.1038/s41590-022-01414-9
-
Authors
Palin, Amy C. http://orcid.org/0000-0002-7724-9563
Alter, Galit http://orcid.org/0000-0002-7680-9215
Crotty, Shane http://orcid.org/0000-0002-6484-6262
Ellebedy, Ali H. http://orcid.org/0000-0002-6129-2532
Lane, M. Chelsea
Lee, F. Eun-Hyung http://orcid.org/0000-0002-6133-5942
Locci, Michela
Malaspina, Angela
Mallia, Conrad
McElrath, M. Juliana
Pulendran, Bali http://orcid.org/0000-0001-6517-4333
Singh, Anjali
D’Souza, M. Patricia
- License Information
-
More Information
Article History
First Online: 1 December 2022
Change Date: 26 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-022-01414-9
Competing interests
: G.A. is a founder and/or equity holder in Systems Seromyx and Leyden Labs, and since October 2022 is an employee of Moderna Therapeutics. S.C. has consulted for GSK, JP Morgan, Citi, Morgan Stanley, Avalia NZ, Nutcracker Therapeutics, University of California, California State Universities, United Airlines, Adagio, and Roche. B.P. serves on the External Immunology Network of GSK, and the scientific advisory board of Medicago. M.P.D., M.C.L., M.L., C.M., M.J.M., A.C.P. and A.S. declare no competing interests.
Free to read: This content has been made available to all.
